PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms)

Launched by WUERZBURG UNIVERSITY HOSPITAL · Sep 15, 2022

Keywords

ClinConnect Summary

The GIPSMA clinical trial is studying a new way to detect and treat certain types of gastrointestinal cancers, specifically gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). This trial will explore whether a special imaging technique called PSMA-PET can help find cancer more accurately and see how the cancer behaves in patients who have just been diagnosed. The researchers want to know if the cancerous tissue shows a specific marker (PSMA), if the imaging can spot more areas of disease, and if the results can help predict how well patients will respond to treatment.

To participate in this trial, you must be an adult (18 years or older) with a newly diagnosed GEP-NEN and have a tissue sample available for testing. It’s important that you haven't started any cancer treatment yet and are willing to follow the study procedures. If you decide to join, you can expect to undergo imaging tests and provide information about your health during follow-up appointments. This trial is currently recruiting participants, and both men and women are welcome to apply, as long as they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed GEP-NEN prior to initiation of guideline-compatible, anti-tumor therapy
• • Available tissue specimen to conduct PSMA expression profiling
• • Male/female, above 18 years old
• • Patients must provide written informed consent
• • Patients must be willing to comply with study procedures and available for follow-up examinations
• Exclusion Criteria:
• • Curative setting
• • Not sufficient tumor tissue available
• • Male Patients: No prostate carcinoma
• • Other malignant neoplasms in patient's history
• • Pregnancy or Breastfeeding
• • Contraindications for PET/CT